Seagen Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1998-01-01
- Employees
- 3.2K
- Market Cap
- -
- Website
- http://www.seagen.com
A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2010-02-02
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT01060904
- Locations
- 🇺🇸
MD Anderson Cancer Center / University of Texas, Houston, Texas, United States
🇺🇸UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT01026415
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States
🇺🇸St. Francis Medical Group Oncology & Hematology Specialists, Indianapolis, Indiana, United States
Cardiac Safety Study of Brentuximab Vedotin (SGN-35)
- Conditions
- Interventions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2014-12-12
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01026233
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma
- First Posted Date
- 2009-11-18
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT01015911
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸UCLA Medical Center / University of California at Los Angeles, Los Angeles, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
- Conditions
- Interventions
- First Posted Date
- 2009-07-28
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT00947856
- Locations
- 🇺🇸
Loyola University Medical Center - Cardinal Bernadin Cancer Center, Maywood, Illinois, United States
🇺🇸The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT00866047
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT00848926
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Washington University School of Medicine, St. Louis, Missouri, United States
🇫🇷Institut Paoli Calmettes, Marseille, France
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
- Conditions
- Interventions
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT00655837
- Locations
- 🇺🇸
Oncology Specialists, Park Ridge, Illinois, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study of ARRY-380 in Patients With Advanced HER2+ Cancer
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00650572
- Locations
- 🇺🇸
The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸The University of Colorado Cancer Center, Aurora, Colorado, United States
🇨🇦British Columbia Cancer Agency, Vancouver, British Columbia, Canada
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
- Conditions
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT00649584
- Locations
- 🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States